Welcome to our dedicated page for Ascendis Pharma news (Ticker: ASND), a resource for investors and traders seeking the latest updates and insights on Ascendis Pharma stock.
Ascendis Pharma A/S (NASDAQ: ASND) is a global biopharmaceutical company that develops therapies using its proprietary TransCon technology platform. This news page aggregates company announcements, clinical updates, financial results, and regulatory milestones that Ascendis discloses through press releases and regulatory channels.
Readers can follow developments related to Ascendis’ commercial products and pipeline, including YORVIPATH (TransCon PTH) for adults with hypoparathyroidism and SKYTROFA (TransCon hGH) for pediatric and adult growth hormone deficiency. News items also cover investigational programs such as TransCon CNP for children with achondroplasia, combination therapy with TransCon CNP and TransCon hGH in the COACH trial, and TransCon IL-2 β/γ in late-line platinum-resistant ovarian cancer.
Updates frequently include information on Phase 2 and Phase 3 clinical trial results, publication of pivotal data in peer-reviewed journals, submissions and reviews of New Drug Applications and Marketing Authorisation Applications, and presentations at major medical and investor conferences. Financial news, such as quarterly results, revenue contributions from YORVIPATH and SKYTROFA, and commentary on the company’s progress toward its long-term vision, is also reported.
Investors and observers can use this page to monitor how Ascendis advances its TransCon-based portfolio across endocrinology, rare diseases, and oncology, as well as to track collaboration news involving partners in regions such as Greater China and Japan. For those following ASND stock, the news flow provides context on the company’s operational performance, regulatory interactions, and clinical milestones over time.
Ascendis Pharma A/S (ASND) announced financial results for 2020, showing a net loss of €419.0 million, or €8.28 per share, compared to €218.0 million in 2019. Revenue decreased to €7.0 million from €13.4 million. R&D expenses rose to €260.9 million, driven by personnel costs and facility expansion. Cash reserves improved to €834.1 million from €598.1 million. Key milestones include preparations for launching TransCon hGH in the U.S. in Q3 2021 and ongoing clinical trials for several product candidates, with important regulatory updates expected in 2021.
Ascendis Pharma A/S (Nasdaq: ASND) announced its participation in ENDO 2021, showcasing seven presentations on its innovative TransCon™ technologies. Key highlights include the first presentation of 6-month data from the phase 2 PaTH Forward trial for adult hypoparathyroidism, demonstrating the potential of TransCon PTH in reducing standard care treatments while maintaining normal serum calcium. Additionally, two-year follow-up data for TransCon hGH (lonapegsomatropin) shows durable results in children with growth hormone deficiency. The presentations will address significant advancements in endocrinology.
Ascendis Pharma A/S (Nasdaq: ASND) will host a conference call on March 10, 2021, at 4:30 p.m. ET to discuss its 2020 financial results and provide a business update. Investors can access the call via dial-in numbers or a live webcast on the company's website. The firm is advancing its TransCon technologies and currently has a pipeline of three endocrinology rare disease candidates and one oncology candidate in clinical development. Ascendis aims to expand into additional therapeutic areas.
Ascendis Pharma A/S (Nasdaq: ASND) has launched Outgrow GHD, an online resource tailored for caregivers of children with growth hormone deficiency (GHD) in the U.S. The initiative aims to improve awareness and support for families navigating challenges associated with GHD. The platform offers educational materials, tools for engagement, and a quiz to discover parenting styles related to GHD.
The resource highlights the need for community support among families affected by rare diseases and will expand to include additional topics relevant to GHD management.
Ascendis Pharma A/S (Nasdaq: ASND) announced its participation in the SVB Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 3:40 p.m. Eastern Time. The presentation will include a business overview and an update on the company's product pipeline, which focuses on addressing unmet medical needs using its innovative TransCon technologies. A live webcast of the event will be accessible through the Ascendis Pharma website, with a replay available for 30 days following the event.
Ascendis Pharma A/S (Nasdaq: ASND) provided an update at the J.P. Morgan Healthcare Conference regarding its strategic roadmap, Vision 3x3. The company anticipates significant milestones in 2021, including advancing five independent TransCon product candidates into clinical development. Key highlights include the expected FDA PDUFA date for TransCon hGH on June 25, 2021, and potential MAA approval in Europe for pediatric growth hormone deficiency by Q4 2021. Additionally, clinical trials for TransCon PTH and TransCon CNP are ongoing, with results expected later this year.
VISEN Pharmaceuticals has secured $150 million in Series B funding, led by Sequoia China, to enhance its clinical development and commercialization efforts in Greater China. This financing round attracted participation from notable investors including OrbiMed and Cormorant. The funds will accelerate development of key endocrinology drug candidates like TransCon hGH and TransCon CNP, which address significant unmet medical needs in the region. CEO Pony Lu emphasized the ongoing Phase 3 study and IND approval as milestones for the company's innovative pipeline.
Ascendis Pharma A/S (Nasdaq: ASND) announced a $12.5 million equity investment in VISEN Pharmaceuticals as part of VISEN's $150 million Series B financing. This move is aligned with Ascendis' Vision 3x3 strategy, aimed at enhancing the global reach of its TransCon endocrinology products. Ascendis retains approximately 44% ownership of VISEN post-financing and expects a non-cash gain in Q1 2021. Key leadership from Ascendis will join VISEN's board to streamline collaboration in advancing clinical pipelines.
Ascendis Pharma A/S (Nasdaq: ASND) announced its participation in the 39th Annual J.P. Morgan Healthcare Conference to be held virtually on January 11, 2021, at 11:40 a.m. Eastern Time. During the event, company executives will provide an overview and updates on the company's pipeline programs, which focus on addressing unmet medical needs through innovative TransCon technologies. The webcast will be accessible on the company's website, with a replay available for 30 days following the conference.
Ascendis Pharma A/S (Nasdaq: ASND) announced the filing of an investigational new drug (IND) application for its TransCon TLR7/8 Agonist with the U.S. FDA. This long-acting prodrug is designed for intratumoral injection, aiming to offer sustained release of resiquimod, enhancing immune response against cancer while minimizing systemic exposure. The company emphasizes this milestone as a potential shift in cancer treatment, leveraging the immune system to target tumors more effectively.